Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Real-World Treatment Patterns and Survival Outcomes of Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With a Selinexor-Containing Triplet-Based Regimen
David Ray, PharmD, MBA, MPH
Executive Director, Global HEOR
Karyopharm Therapeutics